AngioDynamics Appoints John Soto Chief Commercial Officer

AngioDynamics Appoints John Soto Chief Commercial Officer

ALBANY, N.Y., Dec. 11, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a
leading provider of innovative, minimally invasive medical devices for
vascular access, surgery, peripheral vascular disease and oncology, today
announced the appointment of John Soto as Chief Commercial Officer, a newly
created position overseeing the Company's global sales and marketing

Mr. Soto joined AngioDynamics in September 2012 as Senior Vice President of
the Company's Global Peripheral Vascular Franchise. In addition to his new
responsibilities, he will also serve as interim leader of the Peripheral
Vascular Franchise as the Company commences a search to fill the position.
Additionally, Stephen McGill, Senior Vice President and General Manager,
International, will be leaving the Company.

"John Soto has had a tremendous impact on AngioDynamics, driving renewed
strength in our Peripheral Vascular Franchise by successfully integrating the
AngioVac cannula and circuit into our portfolio, stabilizing the fluid
management business and driving growth in the laser segment," said Joseph
DeVivo, President and Chief Executive Officer. "While our International
business has been a good growth driver for the business, it currently accounts
for less than 20% of the Company's global sales. By leveraging John's
expansive background in sales and marketing, I believe we can accelerate our
international performance.

"John's experience spans from sales and marketing to international markets and
regulatory environments, presenting us with a well-rounded leader to hone our
global commercial organization. I believe our new structure will build upon
our progress by uniting our worldwide sales and marketing resources as we
approach the global marketplace," DeVivo continued. "I would also like to
thank Stephen McGill for his service. During his tenure Stephen established
our international presence, including building a strong team and overseeing
the transition to a direct presence in several markets, positioning us well to
take these next steps."

Additionally, AngioDynamics announced its Latin American and Canadian teams
will be combined with the U.S. sales and marketing teams under the new

Previous to joining AngioDynamics, Mr. Soto was Senior Vice President of Smith
& Nephew's Global Hip Franchise. Prior to that, he served as AngioDynamics'
Senior Vice President of Global Sales following the Company's acquisition of
RITA Medical Systems in 2007, where he had served as Executive Vice President
of Global Sales and Vice President of International Operations. Mr. Soto
gained leadership experience at Computer Motion, Tyco Healthcare and U.S.
Surgical. He graduated from the British Royal Navy with a degree in electronic
engineering and has a diploma in medical marketing from the University of
California at Los Angeles, Calif.

About AngioDynamics

AngioDynamics Inc. is a leading provider of innovative, minimally invasive
medical devices used by professional healthcare providers for vascular access,
surgery, peripheral vascular disease and oncology. AngioDynamics' diverse
product lines include market-leading ablation systems, fluid management
systems, vascular access products, angiographic products and accessories,
angioplasty products, drainage products, thrombolytic products and venous
products. More information is available at


AngioDynamics, the AngioDynamics logo and AngioVac are trademarks and/or
registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary.

Safe Harbor

This release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements regarding
AngioDynamics' expected future financial position, results of operations, cash
flows, business strategy, budgets, projected costs, capital expenditures,
products, competitive positions, growth opportunities, plans and objectives of
management for future operations, as well as statements that include the words
such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes,"
"seeks," "estimates," "optimistic," or variations of such words and similar
expressions, are forward-looking statements. These forward looking statements
are not guarantees of future performance and are subject to risks and
uncertainties. Investors are cautioned that actual events or results may
differ from AngioDynamics' expectations. Factors that may affect the actual
results achieved by AngioDynamics include, without limitation, the ability of
AngioDynamics to develop its existing and new products, technological advances
and patents attained by competitors, future actions by the FDA or other
regulatory agencies, domestic and foreign health care reforms and government
regulations, results of pending or future clinical trials, overall economic
conditions, the results of on-going litigation, the effects of economic,
credit and capital market conditions, general market conditions, market
acceptance, foreign currency exchange rate fluctuations, the effects on
pricing from group purchasing organizations and competition, the ability of
AngioDynamics to integrate purchased businesses, including Navilyst Medical
and its products, R&D capabilities, infrastructure and employees as well as
the risk factors listed from time to time in AngioDynamics' SEC filings,
including but not limited to its Annual Report on Form 10-K for the year ended
May 31, 2013. AngioDynamics does not assume any obligation to publicly update
or revise any forward-looking statements for any reason.

CONTACT: Company Contact:
         AngioDynamics, Inc.
         Mark Frost, CFO
         (800) 772-6446 x1981
         Investor Relations Contacts:
         EVC Group, Inc.
         Michael Polyviou/Robert Jones
         (212) 850-6020; (646) 201-5447;
         Media Contact:
         EVC Group, Inc.
         John Carter
         (212) 850-6021
Press spacebar to pause and continue. Press esc to stop.